- Home
- RDIB vs CRDL Comparison
RDIB vs CRDL Comparison
Compare RDIB & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- CRDL
- Stock Information
- Founded
- RDIB 1937
- CRDL 2017
- Country
- RDIB United States
- CRDL Canada
- Employees
- RDIB N/A
- CRDL N/A
- Industry
- RDIB Movies/Entertainment
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDIB Consumer Discretionary
- CRDL Health Care
- Exchange
- RDIB Nasdaq
- CRDL Nasdaq
- Market Cap
- RDIB 140.2M
- CRDL 125.7M
- IPO Year
- RDIB N/A
- CRDL N/A
- Fundamental
- Price
- RDIB $6.81
- CRDL $1.28
- Analyst Decision
- RDIB
- CRDL Strong Buy
- Analyst Count
- RDIB 0
- CRDL 3
- Target Price
- RDIB N/A
- CRDL $9.00
- AVG Volume (30 Days)
- RDIB 2.4K
- CRDL 391.0K
- Earning Date
- RDIB 12-31-2024
- CRDL 11-14-2024
- Dividend Yield
- RDIB N/A
- CRDL N/A
- EPS Growth
- RDIB N/A
- CRDL N/A
- EPS
- RDIB N/A
- CRDL N/A
- Revenue
- RDIB $197,270,000.00
- CRDL N/A
- Revenue This Year
- RDIB N/A
- CRDL N/A
- Revenue Next Year
- RDIB $14.40
- CRDL N/A
- P/E Ratio
- RDIB N/A
- CRDL N/A
- Revenue Growth
- RDIB N/A
- CRDL N/A
- 52 Week Low
- RDIB $5.89
- CRDL $0.79
- 52 Week High
- RDIB $21.34
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- RDIB 54.80
- CRDL 26.78
- Support Level
- RDIB $6.25
- CRDL $1.27
- Resistance Level
- RDIB $6.97
- CRDL $1.46
- Average True Range (ATR)
- RDIB 0.20
- CRDL 0.10
- MACD
- RDIB 0.07
- CRDL -0.00
- Stochastic Oscillator
- RDIB 83.16
- CRDL 3.33
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.